South State Corp raised its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 96.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,884 shares of the life sciences company’s stock after acquiring an additional 4,366 shares during the period. South State Corp’s holdings in Illumina were worth $3,261,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Kaizen Advisory LLC raised its holdings in Illumina by 161.0% during the 2nd quarter. Kaizen Advisory LLC now owns 368 shares of the life sciences company’s stock valued at $103,000 after buying an additional 227 shares during the period. Moneta Group Investment Advisors LLC raised its holdings in Illumina by 2,670.0% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 9,695 shares of the life sciences company’s stock valued at $107,000 after buying an additional 9,345 shares during the period. Sun Life Financial INC raised its holdings in Illumina by 152.5% during the 2nd quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock valued at $111,000 after buying an additional 241 shares during the period. Highstreet Asset Management Inc. purchased a new stake in Illumina during the 3rd quarter valued at $112,000. Finally, Migdal Insurance & Financial Holdings Ltd. raised its holdings in Illumina by 3,192.3% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock valued at $120,000 after buying an additional 415 shares during the period. 90.13% of the stock is currently owned by institutional investors and hedge funds.

In other news, SVP Mostafa Ronaghi sold 10,000 shares of the stock in a transaction on Monday, November 12th. The stock was sold at an average price of $314.63, for a total transaction of $3,146,300.00. Following the transaction, the senior vice president now owns 79,612 shares of the company’s stock, valued at approximately $25,048,323.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Robert S. Epstein sold 1,346 shares of the stock in a transaction on Friday, September 7th. The stock was sold at an average price of $345.14, for a total value of $464,558.44. Following the transaction, the director now directly owns 7,139 shares in the company, valued at approximately $2,463,954.46. The disclosure for this sale can be found here. Insiders have sold a total of 63,464 shares of company stock worth $21,029,631 in the last three months. Corporate insiders own 0.54% of the company’s stock.

ILMN opened at $308.23 on Thursday. Illumina, Inc. has a 12-month low of $203.83 and a 12-month high of $372.61. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46. The firm has a market cap of $45.63 billion, a PE ratio of 77.06, a PEG ratio of 2.30 and a beta of 1.07.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.26. Illumina had a return on equity of 27.10% and a net margin of 21.09%. The business had revenue of $853.00 million for the quarter, compared to the consensus estimate of $825.65 million. During the same quarter in the prior year, the company earned $1.11 EPS. The business’s revenue was up 19.5% compared to the same quarter last year. On average, equities analysts expect that Illumina, Inc. will post 5.75 EPS for the current year.

Several brokerages have commented on ILMN. Zacks Investment Research downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. Barclays upped their price objective on Illumina from $350.00 to $370.00 and gave the company an “overweight” rating in a research report on Wednesday, October 24th. BidaskClub downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Deutsche Bank upped their price objective on Illumina to $350.00 and gave the company a “buy” rating in a research report on Friday, October 12th. Finally, ValuEngine downgraded Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $330.94.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2018/11/15/south-state-corp-purchases-4366-shares-of-illumina-inc-ilmn.html.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Further Reading: Why Dividend Stocks May Be Right for You

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.